Browse AOC3

Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type II membrane protein
Domain PF01179 Copper amine oxidase
PF02727 Copper amine oxidase
PF02728 Copper amine oxidase
Function

Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion. Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis.

> Gene Ontology
 
Biological Process GO:0006805 xenobiotic metabolic process
GO:0009308 amine metabolic process
GO:0009410 response to xenobiotic stimulus
GO:0046677 response to antibiotic
GO:0071466 cellular response to xenobiotic stimulus
Molecular Function GO:0005507 copper ion binding
GO:0008131 primary amine oxidase activity
GO:0016638 oxidoreductase activity, acting on the CH-NH2 group of donors
GO:0016641 oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor
GO:0046982 protein heterodimerization activity
GO:0048037 cofactor binding
GO:0048038 quinone binding
GO:0052593 tryptamine:oxygen oxidoreductase (deaminating) activity
GO:0052594 aminoacetone:oxygen oxidoreductase(deaminating) activity
GO:0052595 aliphatic-amine oxidase activity
GO:0052596 phenethylamine:oxygen oxidoreductase (deaminating) activity
Cellular Component GO:0005769 early endosome
GO:0005902 microvillus
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG hsa00260 Glycine, serine and threonine metabolism
hsa00350 Tyrosine metabolism
hsa00360 Phenylalanine metabolism
hsa00410 beta-Alanine metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-211859: Biological oxidations
R-HSA-1430728: Metabolism
R-HSA-211945: Phase 1 - Functionalization of compounds
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AOC3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between AOC3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
19789345Melanoma; LymphomaInhibit immunityWe found an unexpected defect in tumor angiogenesis in the absence of VAP-1. VAP-1 also selectively enhanced the recruitment of Gr-1+CD11b+ myeloid cells into the tumors. Generation of mice expressing enzymatically inactive VAP-1 showed that the oxidase activity of VAP-1 was necessary to support neoangiogenesis, myeloid cell recruitment, and tumor growth in vivo.
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AOC3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AOC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8010.0333
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9520.494
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6770.428
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5360.418
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5470.824
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5310.856
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5620.261
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1460.361
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0770.956
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7830.633
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.4610.241
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4480.0145
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AOC3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AOC3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AOC3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AOC3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AOC3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AOC3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AOC3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAOC3
Nameamine oxidase, copper containing 3
Aliases VAP1; HPAO; VAP-1; vascular adhesion protein 1; amine oxidase, copper containing 3 (vascular adhesion protei ......
Chromosomal Location17q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AOC3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting AOC3.
ID Name Drug Type Targets #Targets
DB00780PhenelzineSmall MoleculeABAT, AOC3, GPT, GPT2, MAOA, MAOB6
DB01275HydralazineSmall MoleculeAOC3, P4HA12
DB043346-hydroxydopa quinoneSmall MoleculeAOC31